Boehringer Ingelheim Pharma GmbH & Co.KG (primary (blister) and secondary packaging, labeling, quality control, microbiological purity quality control and batch release of the medicinal product)
UkraineAll drugs from this manufacturer
-
The drug is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis.
Dosage form: capsules, soft gelatin
Active substance Dosage nintedanib 100 mg ATC: L01EX09
-
The drug is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis.
Dosage form: capsules, soft gelatin
Active substance Dosage nintedanib 150 mg ATC: L01EX09